Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGUS: EPX-100 (clemizole hydrochloride) as adjunctive therapy in Dravet syndrome
2021-003425-30Phase 2Suspended
- Sponsor
- Epygenix Therapeutics, Inc.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Dravet syndrome comparing EPX-100 adjunctive arm with Placebo adjunctive arm (2 arms). Started Mar 2022; status: suspended.
02
Drugs
clemizole
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on 2021-003425-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003425-30.